Billiontoone (NASDAQ:BLLN) Cut to "Strong Sell" at Zacks Research

Key Points

• Zacks Research downgraded Billiontoone to “strong sell” from “hold,” although analyst opinions remain mixed. The stock has six Buy, two Hold, and two Sell ratings, with an average target price of $126.71.
• Billiontoone reported quarterly EPS of $0.15, in line with expectations, and revenue of $109.45 million. Shares opened at $92.32, below their 50-day moving average of $114.66 and well below the 12-month high of $150.44.
• Insiders have been substantial sellers: executives sold 224,883 shares worth approximately $25.7 million over the past 90 days, including a 32,500-share sale by CEO Oguzhan Atay under a pre-arranged Rule 10b5-1 plan.

Billiontoone (NASDAQ:BLLN - Get Free Report) was downgraded by stock analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Monday, Zacks reports.

Other equities analysts have also issued research reports about the stock. Guggenheim initiated coverage on shares of Billiontoone in a report on Monday, June 29th. They set a "buy" rating and a $125.00 price target on the stock. Weiss Ratings raised Billiontoone from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday, June 23rd. JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an "overweight" rating for the company in a research note on Thursday, August 6th. Wall Street Zen lowered Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, BTIG Research cut their price objective on Billiontoone from $142.00 to $130.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Billiontoone has an average rating of "Hold" and an average target price of $126.71.

Billiontoone Trading Up 1.8%

Shares of BLLN stock opened at $92.32 on Monday. Billiontoone has a twelve month low of $61.96 and a twelve month high of $150.44. The stock's fifty day simple moving average is $114.66 and its 200 day simple moving average is $95.33. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.36 billion and a P/E ratio of 131.89.

Billiontoone (NASDAQ:BLLN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts' consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The firm had revenue of $109.45 million for the quarter. As a group, sell-side analysts predict that Billiontoone will post 0.83 EPS for the current fiscal year.

Insider Transactions at Billiontoone

In related news, CEO Oguzhan Atay sold 32,500 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.95, for a total transaction of $4,450,875.00. Following the sale, the chief executive officer owned 20,000 shares in the company, valued at $2,739,000. This represents a 61.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Nancy Joann Johnson sold 10,582 shares of the firm's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54. Following the sale, the insider directly owned 21,900 shares of the company's stock, valued at $2,200,293. This represents a 32.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 224,883 shares of company stock valued at $25,698,744. Corporate insiders own 50.22% of the company's stock.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently modified their holdings of the business. UBS Group AG acquired a new stake in shares of Billiontoone in the 4th quarter valued at about $2,586,000. Sigma Planning Corp bought a new position in Billiontoone in the fourth quarter worth approximately $409,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone in the fourth quarter valued at approximately $82,000. Geode Capital Management LLC acquired a new stake in Billiontoone in the fourth quarter valued at approximately $6,716,000. Finally, Seven Grand Managers LLC bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $2,046,000.

Billiontoone Company Profile

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source